Accuracy of endoscopic staging and targeted biopsies for routine gastric intestinal metaplasia and gastric atrophy evaluation study protocol of a prospective, cohort study: the estimate study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
18 09 2019
Historique:
entrez: 21 9 2019
pubmed: 21 9 2019
medline: 21 10 2020
Statut: epublish

Résumé

Patients with chronic atrophic gastritis (CAG) and intestinal metaplasia (IM) are at risk of developing gastric adenocarcinoma. Their diagnosis and management currently rely on histopathological guidance after random endoscopic biopsy sampling (Sydney biopsy strategy). This approach has significant flaws such as under-diagnosis, poor reproducibility and poor correlation between endoscopy and histology. This prospective, international multicentre study aims to establish whether endoscopy-led risk stratification accurately and reproducibly predicts CAG and IM extent and disease stage. Patients with CAG and/or IM on standard white light endoscopy (WLE) will be prospectively identified and invited to undergo a second endoscopy performed by an expert endoscopist using enhanced endoscopic imaging techniques with virtual chromoendoscopy. Extent of CAG/IM will be endoscopically staged with enhanced imaging and compared with standard WLE. Histopathological risk stratification through targeted biopsies will be compared with endoscopic disease staging and to random biopsy staging on WLE as a reference. At least 234 patients are required to show a 10 % difference in sensitivity and accuracy between enhanced imaging endoscopy-led staging and the current biopsy-led staging protocol of gastric atrophy with a power (beta) of 80 % and a 0.05 probability of a type I error (alpha). The study was approved by the respective Institutional Review Boards (Netherlands: MEC-2018-078; UK: 19/LO/0089). The findings will be published in peer-reviewed journals and presented at scientific meetings. NTR7661; Pre-results.

Identifiants

pubmed: 31537576
pii: bmjopen-2019-032013
doi: 10.1136/bmjopen-2019-032013
pmc: PMC6756576
doi:

Banques de données

NTR
['NTR7661']

Types de publication

Clinical Trial Protocol Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e032013

Subventions

Organisme : Medical Research Council
ID : MR/S022244/1
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

World J Gastroenterol. 2008 Feb 28;14(8):1149-55
pubmed: 18300338
Endoscopy. 2006 Aug;38(8):819-24
pubmed: 17001572
Gut. 2019 Apr;68(4):585-593
pubmed: 29875257
PLoS One. 2015 Nov 10;10(11):e0142080
pubmed: 26556485
BMC Gastroenterol. 2015 Aug 04;15:95
pubmed: 26239636
Jpn J Clin Oncol. 2013 Nov;43(11):1157-8
pubmed: 24186939
Dig Dis Sci. 2013 Apr;58(4):1084-90
pubmed: 23086114
Gut. 2019 Sep;68(9):1545-1575
pubmed: 31278206
JAMA. 2010 May 5;303(17):1723-8
pubmed: 20442388
World J Gastroenterol. 2013 Apr 7;19(13):2092-6
pubmed: 23599630
Endoscopy. 2016 Aug;48(8):723-30
pubmed: 27280384
World J Gastroenterol. 2014 Apr 28;20(16):4483-90
pubmed: 24782601
Clin Gastroenterol Hepatol. 2015 Sep;13(9):1592-600.e1
pubmed: 25857683
Endoscopy. 2019 Jun;51(6):515-521
pubmed: 30577062
Gastric Cancer. 2018 Jul;21(4):579-587
pubmed: 29460004
Endoscopy. 2019 Apr;51(4):365-388
pubmed: 30841008
Eur J Epidemiol. 2011 Jan;26(1):23-8
pubmed: 21086022
Endoscopy. 2016 Nov;48(11):1029-1045
pubmed: 27711949
Endosc Int Open. 2014 Jun;2(2):E46-50
pubmed: 26135259
Adv Med Sci. 2011;56(2):145-50
pubmed: 22037174
Aliment Pharmacol Ther. 2013 Nov;38(10):1292-302
pubmed: 24134499
Surg Endosc. 2017 May;31(5):2140-2148
pubmed: 27604367
BMJ Open. 2016 Nov 14;6(11):e012799
pubmed: 28137831
Endoscopy. 2012 Jan;44(1):74-94
pubmed: 22198778
Am J Surg Pathol. 1996 Oct;20(10):1161-81
pubmed: 8827022

Auteurs

Stella A V Nieuwenburg (SAV)

Gastroenterology & Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

William W Waddingham (WW)

Endoscopy, University College London Hospital, London, UK.
UCL Cancer Institute, University College London, London, UK.

David Graham (D)

Endoscopy, University College London Hospital, London, UK.

Manuel Rodriguez-Justo (M)

Pathology, University College London Hospital, London, UK.

Katharina Biermann (K)

Pathology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Ernst J Kuipers (EJ)

Gastroenterology & Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Matthew Banks (M)

Endoscopy, University College London Hospital, London, UK.

Marnix Jansen (M)

Endoscopy, University College London Hospital, London, UK.
Pathology, University College London Hospital, London, UK.

Manon C W Spaander (MCW)

Gastroenterology & Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands v.spaander@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH